Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer

References

• Early Breast Cancer Trialists’ Collaborative Group: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of randomized trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Thrane S, Pedersen AM, Thomsen MBH, et al. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015;34:4199–4210.
   PubMed Web of Science ®Google Scholar
• Hole S, Pedersen AM, Lykkesfeldt AE, et al. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res Treat. 2015;149:715–726.
   PubMed Web of Science ®Google Scholar
• Larsen SL, Yde CW, Laenkholm AV, et al. Aurora B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. BMC Cancer. 2015;15:239.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115.
   PubMed Web of Science ®Google Scholar
• Sasai K, Treekitkammonkol T, Kai K, et al. Functional significance of Aurora kinase-p53 protein interactions. Front Oncol. 2016;6:247.
   PubMed Web of Science ®Google Scholar
• Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic Aurora-A pathway. Int J Biol Sci. 2009;5:758–762.
   PubMed Web of Science ®Google Scholar
• Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors – rising stars in cancer therapeutics? Mol Cancer Therap. 2010;9:267–278.
   Web of Science ®Google Scholar
• Siggelkow W, Boehm D, Gebhard S, et al. Expression of Aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer. 2012;12:562.
   PubMed Web of Science ®Google Scholar
• Ali HR, Dawson SJ, Blows FM, et al. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer. 2012;106:1798–1806.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto-Ibusuki M, Yamamoto Y, et al. A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer. BMC Cancer. 2013;13:217.
   PubMed Web of Science ®Google Scholar
• Zheng XQ, Guo JP, Yang H, et al. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer. Oncogene. 2014;33:4985–4996.
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757.
   PubMed Web of Science ®Google Scholar
• Henriksen KL, Rasmussen BB, Lykkesfeldt AE, et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397–404.
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168.
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–1108.
   PubMed Web of Science ®Google Scholar
• Nadler Y, Camp RL, Schwartz C, et al. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res. 2008;14:4455–4462.
   PubMed Web of Science ®Google Scholar
• Cirak Y, Furuncuoglu Y, Yapicier O, et al. Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis. J BUON. 2015;20:1414–1419.
   PubMed Web of Science ®Google Scholar
• Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569–5575.
   PubMed Web of Science ®Google Scholar
• Xu J, Xing W, Zhou W, et al. Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS One. 2013;8:e56919.
   PubMed Web of Science ®Google Scholar
• Thrane S, Lykkesfeldt AE, Larsen M, et al. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 2013;139:71–80.
   PubMed Web of Science ®Google Scholar
• Hole S, Pedersen AM, Hansen S, et al. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015;46:1481–1490.
   PubMed Web of Science ®Google Scholar